Promis Neurosciences Inc (PMN) — Who's Buying and Selling (13F, Q2 2026)

PMN ranks #7725 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PMN is a top-conviction position for Ally Bridge Group — at 7.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PMN belongs to Jupiter Topco LLC, but the position matters far more to Ally Bridge Group, who has 7.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ally Bridge Group has added to its PMN position for two straight quarters, increasing it by $6.5M to reach $8.2M today.

PMN is up 4.7% today, and institutions have been net buyers of $4.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PMN reported a net loss of $39.7M in its latest fiscal year.

• Not yet profitable — net loss of $39.7M in the latest fiscal year
• Net income declined year over year, from $2.8M to -$39.7M
• Operating cash flow was negative, using $28.1M in cash
• Current ratio of 0.88x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)